Results 51 to 60 of about 25,773 (228)

Advances in Viral Markers for Predicting Functional Cure of Chronic Hepatitis B

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) loss, is achieved by only a minority of patients with chronic hepatitis B (CHB); early identification of likely responders may improve cure rates and reduce costs. However, responses to antiviral therapy vary considerably, necessitating reliable hepatitis B virus (HBV) viral ...
Xinrong Lu   +3 more
wiley   +1 more source

"IL28B polymorphism in chronic HBV infection: the CC allele does not correlate with the phase of the infection nor with HBsAg clearance in IFN treated patients". [PDF]

open access: yes, 2012
IL28B polymorphism (IL28Bp) is associated with spontaneous and treatment induced HCV clearance, whereas its role in HBV infection is still debated. We analysed the correlation between IL28Bp and phase and outcome of HBV infection and HBsAg clearance in ...
CHERUBINI, BEATRICE
core  

Difference in the incidence of YMDD mutation between HBeAg positive and HBeAg negative patients.

open access: yes, 2012
Difference in the incidence of YMDD mutation between HBeAg positive and HBeAg negative patients.
Li Chen (5749)   +10 more
core   +1 more source

Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters

open access: yesJHEP Reports, 2021
Summary: Background & Aims: We aimed to investigate how viral quasispecies of the HBV whole genome evolves and diversifies in response to HBeAg seroconversion and viral control utilising next-generation sequencing (NGS).
Su-Ru Lin   +16 more
doaj   +1 more source

The Emerging Role of China in the Innovation, Individualization, and Translation of Antiviral Therapeutics for Chronic Hepatitis B

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
This perspective outlines China's contributions toward functional‐cure‐oriented antiviral therapies for chronic hepatitis B, summarizing key clinical data on bepirovirsen and domestic drug pipelines with balanced coverage of both promising and disappointing trial results.
Dandan Weng, Zhujun Cao, Qing Xie
wiley   +1 more source

Treating Immune-tolerant Hepatitis B

open access: yes, 2017
Hepatitis B virus (HBV) infection is a major cause of cirrhosis and hepatocellular carcinoma worldwide. On the basis of virus-host interactions, the natural history of HBV carriers can be divided into four chronological phases.
Tseng, T-C;Kao, J-H, 高嘉宏
core   +1 more source

A survey of the frequency of HBsAg+ status in pregnant women attending health centers in Ahwaz

open access: yesPayesh, 2004
Objective(s): To estimate a frequency of HBsAg prevalence by a simple sampling method on 120 pregnant women attending health centers in Ahwaz city between March and December 1998.
Mohammad jaffari R   +3 more
doaj  

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux   +6 more
wiley   +1 more source

AUC of ALT associated with significant histological characteristics in HBeAg positive and HBeAg negative patients.

open access: yes, 2015
A: AUC of ALT associated with significant necroinflammatory scores in HBeAg positive patients; B: AUC of ALT associated with significant fibrosis scores in HBeAg positive patients; C: AUC of ALT associated with significant necroinflammatory scores in ...
Li Chen (5749)   +4 more
core   +1 more source

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy